Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 Mar 01; 116(5):1272-80.